Hyderabad: MSN Labs, has marked the unveiling of its new & dedicated Oncology Division, ‘Oncology Original Medicine’ by launching CabolongTM – India’s first branded generic of Cabozantinib for treatment of renal cell carcinoma.
“The division will focus on presenting a comprehensive range of affordable High quality, Bio-Equivalent generic oncology medicines benefitting patients in India. MSN already holds a distinguished track record of launching early branded generics of 14 Oncology molecules and making its presence felt in the US, Europe and emerging markets”, said a release issued here.
This initiative comes at a crucial juncture wherein the cancer cases in the country are likely to increase to 15.6 lakhs by 2025 — a 12% increase from current estimated cases — based on current trends, according to the National Cancer Registry Programme Report 2020.